KalVista Pharmaceuticals, Inc. (KALV)

NASDAQ: KALV · IEX Real-Time Price · USD
7.45
+0.64 (9.40%)
At close: Mar 29, 2023, 4:00 PM
7.60
+0.15 (2.01%)
After-hours: Mar 29, 2023, 5:51 PM EDT
9.4%
Market Cap 254.56M
Revenue (ttm) n/a
Net Income (ttm) -90.72M
Shares Out 34.17M
EPS (ttm) -3.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 409,110
Open 6.83
Previous Close 6.81
Day's Range 6.83 - 7.46
52-Week Range 4.12 - 17.06
Beta 1.11
Analysts Buy
Price Target 19.72 (+164.7%)
Earnings Date Mar 9, 2023

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Thomas Andrew Crockett M.B.A.
Employees 105
Stock Exchange NASDAQ
Ticker Symbol KALV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $19.72, which is an increase of 164.70% from the latest price.

Price Target
$19.72
(164.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate rev...

1 week ago - Zacks Investment Research

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commerc...

3 weeks ago - Business Wire

Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

3 weeks ago - Zacks Investment Research

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

1 month ago - Business Wire

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

1 month ago - Business Wire

KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

1 month ago - Business Wire

KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

1 month ago - Business Wire

What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock

KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term...

1 month ago - Zacks Investment Research

Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

1 month ago - Zacks Investment Research

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

1 month ago - Business Wire

KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

1 month ago - Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted two ne...

2 months ago - Business Wire

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

3 months ago - Business Wire

KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

3 months ago - Business Wire

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comme...

4 months ago - Business Wire

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

4 months ago - Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.

5 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). Such investors ar...

6 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). S...

6 months ago - Newsfile Corp

KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

6 months ago - Business Wire

KalVista (KALV) Stock Continues to Decline: Here's Why

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

6 months ago - Zacks Investment Research

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?

KalVista Pharmaceuticals (NASDAQ: KALV) is trending on popular financial social media right now, but it's not good news. Reportedly, there were safety-related concerns over KalVista's clinical study ...

6 months ago - InvestorPlace